A Phase 2/3 interventional study of Valsartan + amlodipine 40/2.5 mg and Valsartan + amlodipine 40/5 mg in Essential Hypertension, sponsored by Novartis Pharmaceuticals. Completed at 1 site in Japan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2011-04-29.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing valsartan in Essential Hypertension — 2 open to participants now, 2 under way, 1 of them phase 3. Valsartan · Essential Hypertension.
Among the 10 studies testing valsartan in Essential Hypertension, this one has the largest enrollment, is the only one that started in 2006, is the only one in phase 2/3, and was the 2nd registered.
480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.
Browse Essential Hypertension studies →2 of the 10 studies testing valsartan in Essential Hypertension are open now, in 1 country. Recruiting first, the newest first:
Shandong New Time Pharmaceutical Co., LTD · Sites in China
Ages 6–17
Sichuan Academy of Medical Sciences · Sites in China
Ages 18+
By country, each count listing its studies:
Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.
This study: 20 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 5 · Phase 4 4
First in 2005; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,474 is above the median of 144 across 407 interventional studies indexed under Essential Hypertension.
Median enrollment 392 across the 10 interventional studies. Of the 8 that completed or were terminated, 3 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 10 have an industry lead sponsor. The 7 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
27 studies in Essential Hypertension by Novartis: none open now, none under way, none of them phase 3. Of 27 finished, 19 (70%) have results posted.
Among the 27 studies in Essential Hypertension by Novartis, this one has the largest enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2006, is the only one in phase 2/3, and was the 4th registered.
Novartis’s Essential Hypertension studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing valsartan in Essential Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 27 in Essential Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of fixed combination of valsartan (40 mg and 80 mg) and amlodipine (2.5 mg and 5 mg), valsartan and amlodipine alone, and placebo in reducing blood pressure. The study will investigate the dose response relationship for the combinations, monotherapies, and placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with essential hypertension measured by electronic hemodynamometer. - - Patients must satisfy the following criteria.
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Valsartan + amlodipine 40/2.5 mg
Drug: Valsartan + amlodipine 40/5 mg
Drug: Valsartan + amlodipine 80/2.5 mg
Drug: Valsartan + amlodipine 80/5 mg
Drug: Valsartan 40 mg
Drug: Valsartan 80 mg
Drug: Amlodipine 2.5 mg
Drug: Amlodipine 5 mg
Drug: Placebo
Valsartan + amlodipine 40/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
Valsartan + amlodipine 40/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily
Valsartan + amlodipine 80/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
Valsartan + amlodipine 80/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily
Valsartan 40 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
Valsartan 80 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
Amlodipine 2.5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily
Amlodipine 5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily
4 tablet and 2 capsule placebos taken once daily
Change in Mean Sitting Diastolic Blood Pressure (MSDBP) From Baseline to End of Study (Week 8)
At study entry, blood pressure was measured in both arms using a standard method described in the protocol. The arm with the higher diastolic BP reading was used for the measurements at all subsequent visits. Blood pressure in the sitting position was measured after resting in a seated position for at least 5 minutes. The measurement was repeated a total of 3 times at intervals of 1 to 2 minutes. A negative number indicates lowered blood pressure.
Time frame: Baseline to end of study (Week 8)
Change in Mean Sitting Systolic Blood Pressure (MSSBP) From Baseline to End of Study (Week 8)
At study entry, blood pressure was measured in both arms using a standard method described in the protocol. The arm with the higher diastolic BP reading was used for the measurements at all subsequent visits. Blood pressure in the sitting position was measured after resting in a seated position for at least 5 minutes. The measurement was repeated a total of 3 times at intervals of 1 to 2 minutes. A negative number indicates lowered blood pressure.
Time frame: Baseline to end of study (Week 8)
Percentage of Patients Achieving MSDBP < 90 mmHg or a => 10 mm Hg Decrease Compared to Baseline at the End of the Study (Week 8)
At study entry, blood pressure was measured in both arms using a standard method described in the protocol. The arm with the higher diastolic BP reading was used for the measurements at all subsequent visits. Blood pressure in the sitting position was measured after resting in a seated position for at least 5 minutes. The measurement was repeated a total of 3 times at intervals of 1 to 2 minutes. A negative number indicates lowered blood pressure.
Time frame: Baseline to end of study (Week 8)
Percentage of Patients Achieving MSDBP < 90mmHg at the End of the Study (Week 8)
At study entry, blood pressure was measured in both arms using a standard method described in the protocol. The arm with the higher diastolic BP reading was used for the measurements at all subsequent visits. Blood pressure in the sitting position was measured after resting in a seated position for at least 5 minutes. The measurement was repeated a total of 3 times at intervals of 1 to 2 minutes. A negative number indicates lowered blood pressure.
Time frame: Baseline to end of study (Week 8)
Percentage of Patients Achieving MSDBP < 90 mm Hg and MSSBP < 140 mm Hg at the End of the Study (Week 8)
At study entry, blood pressure was measured in both arms using a standard method described in the protocol. The arm with the higher diastolic BP reading was used for the measurements at all subsequent visits. Blood pressure in the sitting position was measured after resting in a seated position for at least 5 minutes. The measurement was repeated a total of 3 times at intervals of 1 to 2 minutes. A negative number indicates lowered blood pressure.
Time frame: Baseline to end of study (Week 8)
| Milestone | Valsartan + Amlodipine 40/2.5 mg | Valsartan + Amlodipine 40/5 mg | Valsartan + Amlodipine 80/2.5 mg | Valsartan + Amlodipine 80/5 mg | Valsartan 40 mg | Valsartan 80 mg | Amlodipine 2.5 mg | Amlodipine 5 mg | Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Started | 159 | 167 | 160 | 162 | 169 | 163 | 161 | 161 | 166 |
| Completed | 154 | 164 | 157 | 160 | 159 | 154 | 154 | 151 | 148 |
| Not completed | 5 | 3 | 3 | 2 | 10 | 9 | 7 | 10 | 18 |
| Withdrew: Adverse event | 2 | 2 | 0 | 1 | 4 | 6 | 2 | 3 | 8 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 5 | 3 |
| Withdrew: Withdrawal by subject | 2 | 0 | 2 | 1 | 4 | 0 | 2 | 2 | 2 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 1 | 3 | 3 | 0 | 5 |
At study entry, blood pressure was measured in both arms using a standard method described in the protocol. The arm with the higher diastolic BP reading was used for the measurements at all subsequent visits. Blood pressure in the sitting position was measured after resting in a seated position for at least 5 minutes. The measurement was repeated a total of 3 times at intervals of 1 to 2 minutes. A negative number indicates lowered blood pressure.
| mm Hg | Valsartan + Amlodipine 40/2.5 mg | Valsartan + Amlodipine 40/5 mg | Valsartan + Amlodipine 80/2.5 mg | Valsartan + Amlodipine 80/5 mg | Valsartan 40 mg | Valsartan 80 mg | Amlodipine 2.5 mg | Amlodipine 5 mg | Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Change in Mean Sitting Diastolic Blood Pressure (MSDBP) From Baseline to End of Study (Week 8) | -13.5 ± 0.62 | -16.5 ± 0.60 | -12.6 ± 0.62 | -17.0 ± 0.61 | -8.5 ± 0.60 | -8.8 ± 0.61 | -10.3 ± 0.61 | -13.4 ± 0.61 | -4.8 ± 0.61 |
At study entry, blood pressure was measured in both arms using a standard method described in the protocol. The arm with the higher diastolic BP reading was used for the measurements at all subsequent visits. Blood pressure in the sitting position was measured after resting in a seated position for at least 5 minutes. The measurement was repeated a total of 3 times at intervals of 1 to 2 minutes. A negative number indicates lowered blood pressure.
| mm Hg | Valsartan + Amlodipine 40/2.5 mg | Valsartan + Amlodipine 40/5 mg | Valsartan + Amlodipine 80/2.5 mg | Valsartan + Amlodipine 80/5 mg | Valsartan 40 mg | Valsartan 80 mg | Amlodipine 2.5 mg | Amlodipine 5 mg | Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Change in Mean Sitting Systolic Blood Pressure (MSSBP) From Baseline to End of Study (Week 8) | -16.7 ± 0.88 | -22.0 ± 0.86 | -16.9 ± 0.88 | -22.9 ± 0.87 | -9.3 ± 0.85 | -9.5 ± 0.87 | -13.6 ± 0.87 | -16.6 ± 0.87 | -4.4 ± 0.86 |
At study entry, blood pressure was measured in both arms using a standard method described in the protocol. The arm with the higher diastolic BP reading was used for the measurements at all subsequent visits. Blood pressure in the sitting position was measured after resting in a seated position for at least 5 minutes. The measurement was repeated a total of 3 times at intervals of 1 to 2 minutes. A negative number indicates lowered blood pressure.
| Percentage of patients | Valsartan + Amlodipine 40/2.5 mg | Valsartan + Amlodipine 40/5 mg | Valsartan + Amlodipine 80/2.5 mg | Valsartan + Amlodipine 80/5 mg | Valsartan 40 mg | Valsartan 80 mg | Amlodipine 2.5 mg | Amlodipine 5 mg | Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Percentage of Patients Achieving MSDBP < 90 mmHg or a => 10 mm Hg Decrease Compared to Baseline at the End of the Study (Week 8) | 77.4 | 88.0 | 80.6 | 86.4 | 52.1 | 47.9 | 62.1 | 74.5 | 36.1 |
At study entry, blood pressure was measured in both arms using a standard method described in the protocol. The arm with the higher diastolic BP reading was used for the measurements at all subsequent visits. Blood pressure in the sitting position was measured after resting in a seated position for at least 5 minutes. The measurement was repeated a total of 3 times at intervals of 1 to 2 minutes. A negative number indicates lowered blood pressure.
| Percentage of patients | Valsartan + Amlodipine 40/2.5 mg | Valsartan + Amlodipine 40/5 mg | Valsartan + Amlodipine 80/2.5 mg | Valsartan + Amlodipine 80/5 mg | Valsartan 40 mg | Valsartan 80 mg | Amlodipine 2.5 mg | Amlodipine 5 mg | Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Percentage of Patients Achieving MSDBP < 90mmHg at the End of the Study (Week 8) | 67.3 | 82.6 | 72.5 | 80.9 | 46.2 | 41.1 | 55.3 | 67.1 | 31.9 |
At study entry, blood pressure was measured in both arms using a standard method described in the protocol. The arm with the higher diastolic BP reading was used for the measurements at all subsequent visits. Blood pressure in the sitting position was measured after resting in a seated position for at least 5 minutes. The measurement was repeated a total of 3 times at intervals of 1 to 2 minutes. A negative number indicates lowered blood pressure.
| Percentage of patients | Valsartan + Amlodipine 40/2.5 mg | Valsartan + Amlodipine 40/5 mg | Valsartan + Amlodipine 80/2.5 mg | Valsartan + Amlodipine 80/5 mg | Valsartan 40 mg | Valsartan 80 mg | Amlodipine 2.5 mg | Amlodipine 5 mg | Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Percentage of Patients Achieving MSDBP < 90 mm Hg and MSSBP < 140 mm Hg at the End of the Study (Week 8) | 55.3 | 75.4 | 59.4 | 72.2 | 33.1 | 30.1 | 41.0 | 57.1 | 18.7 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 2/166 (1.2%) | 17/166 (10.2%) |
| Valsartan 40 mg | — | 0/169 (0%) | 23/169 (13.6%) |
| Valsartan 80 mg | — | 0/163 (0%) | 19/163 (11.7%) |
| Amlodipine 2.5 mg | — | 1/161 (0.6%) | 12/161 (7.5%) |
| Valsartan + Amlodipine 40/2.5 mg | — | 0/159 (0%) | 17/159 (10.7%) |
| Valsartan + Amlodipine 80/2.5 mg | — | 1/160 (0.6%) | 9/160 (5.6%) |
| Amlodipine 5 mg | — | 0/161 (0%) | 12/161 (7.5%) |
| Valsartan + Amlodipine 40/5 mg | — | 1/167 (0.6%) | 20/167 (12%) |
| Valsartan + Amlodipine 80/5 mg | — | 0/162 (0%) | 14/162 (8.6%) |
| Event | Placebo | Valsartan 40 mg | Valsartan 80 mg | Amlodipine 2.5 mg | Valsartan + Amlodipine 40/2.5 mg | Valsartan + Amlodipine 80/2.5 mg | Amlodipine 5 mg | Valsartan + Amlodipine 40/5 mg | Valsartan + Amlodipine 80/5 mg |
|---|---|---|---|---|---|---|---|---|---|
| Compression fractureInjury, poisoning and procedural complications | 0/166 | 0/169 | 0/163 | 0/161 | 0/159 | 1/160 | 0/161 | 0/167 | 0/162 |
| Supraventricular tachycardiaCardiac disorders | 0/166 | 0/169 | 0/163 | 1/161 | 0/159 | 0/160 | 0/161 | 0/167 | 0/162 |
| Ulcerative keratitisEye disorders | 1/166 | 0/169 | 0/163 | 0/161 | 0/159 | 0/160 | 0/161 | 0/167 | 0/162 |
| Pyelonephritis acuteInfections and infestations | 1/166 | 0/169 | 0/163 | 0/161 | 0/159 | 0/160 | 0/161 | 0/167 | 0/162 |
| GastroenteritisInfections and infestations | 0/166 | 0/169 | 0/163 | 0/161 | 0/159 | 0/160 | 0/161 | 1/167 | 0/162 |
| Event | Placebo | Valsartan 40 mg | Valsartan 80 mg | Amlodipine 2.5 mg | Valsartan + Amlodipine 40/2.5 mg | Valsartan + Amlodipine 80/2.5 mg | Amlodipine 5 mg | Valsartan + Amlodipine 40/5 mg | Valsartan + Amlodipine 80/5 mg |
|---|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 17/166 | 23/169 | 19/163 | 12/161 | 17/159 | 9/160 | 12/161 | 20/167 | 14/162 |
| Age Continuous(years) | Valsartan + Amlodipine 40/2.5 mg | Valsartan + Amlodipine 40/5 mg | Valsartan + Amlodipine 80/2.5 mg | Valsartan + Amlodipine 80/5 mg | Valsartan 40 mg | Valsartan 80 mg | Amlodipine 2.5 mg | Amlodipine 5 mg | Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 53.9 ± 10.34 | 52.8 ± 10.70 | 52.8 ± 10.76 | 54.1 ± 9.75 | 52.9 ± 10.08 | 52.6 ± 11.29 | 53.2 ± 10.83 | 54.4 ± 10.67 | 51.5 ± 10.58 | 53.1 ± 10.57 |
| Sex: Female, Male(Participants) | Valsartan + Amlodipine 40/2.5 mg | Valsartan + Amlodipine 40/5 mg | Valsartan + Amlodipine 80/2.5 mg | Valsartan + Amlodipine 80/5 mg | Valsartan 40 mg | Valsartan 80 mg | Amlodipine 2.5 mg | Amlodipine 5 mg | Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 46 | 49 | 40 | 39 | 38 | 49 | 49 | 40 | 55 | 405 |
| Male | 113 | 118 | 120 | 123 | 131 | 114 | 112 | 121 | 111 | 1063 |
The record gives a start of Nov 2006, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2011, 2 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Valsartan · Amlodipine